TCMD Tactile Systems Technology, Inc.

XNAS 26.09 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

TCMD $26.09 —
Key stats
$26.09
52-Week Range
$20.53 – $37.77
YTD
-4.78%
IV Rank (30D)
27.86
Straddle Price
$3.20
P/C Vol Ratio
0.18
Market Cap
$0.6B
Open
$26.41
Day Range
$25.81 – $26.80
Volume
147,219
Prev Close
$26.42
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY1.19
Cost of Equity (CAPM)11.71% (VRP-adj)
WACC11.59%
Volatility Risk Premium+30.6pp (IV − HV30), ERP adj +50bps
Effective Tax Rate33.9%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$0.0B
Return on Equity (TTM)10.5%
Book / Price37.9% — banking bias active (P/B is primary)
Gross Margin (TTM)77.0%
FCF Margin (TTM)8.1%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
Market-Implied Growth+11.1% (reverse-DCF on current price)
SMA 50$23.53 (Market Anchor value)
SMA 20 / Bollinger Mid$25.11
Bollinger Width / SMA2024.9% (drives anchor stability)
Net Debt$-0.1B
Market Cap$1B
Peers used for multiples: ENOV, GEHC, MD, OSCR (filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
45%
20-Day Fair Value
≈ by Dec 17, 2026
$26.32
α -0.4% rank 23%
conviction
41%
40-Day Fair Value
≈ by Jan 15, 2027
$26.54
α +0.5% rank 21%
conviction
32%
60-Day Fair Value
≈ by Feb 15, 2027
$26.68
α +1.0% rank 16%
conviction
45%
MethodImplied PriceWeightDetail
DCF $10.44 37%
DDM (Gordon) n/a 0%
Peer P/E $16.93 11% median 16.6× · 3 peers
Peer EV/EBITDA $20.77 11% median 9.5× · 4 peers
Peer P/B $30.37 11% median 3.1× · 4 peers
Peer P/S $15.23 11% median 1.0× · 4 peers
Market Anchor (SMA50) $23.53 19% stability 26% (BB-width)
Options Expected (B-L 30d) $26.50 0% 5 strikes · skew -1.23
As of 2026-11-18 · updated
About
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
Exchange
XNAS
Market Cap
$0.6B
Employees
1,086
List Date
2016-07-28
CIK
0001027838
Last Earnings
Nov 2 after close · +8.4% vs ±21.8% expected
Next Earnings
~Feb 16, 2027 (estimated)
Headquarters
Minneapolis, MN
Homepage
https://www.tactilemedical.com

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan18.15%-20.07%9.45%6.53%2.28%5.33%3.61%
Feb-8.25%30.35%9.72%-3.30%-17.59%1.95%2.15%
Mar3.03%0.15%13.48%5.86%-6.17%-10.79%0.93%
Apr7.24%-21.49%11.43%-12.13%3.82%-11.36%-3.75%
May-8.30%-43.27%13.19%-11.23%-28.56%7.51%-11.78%
Jun-2.79%-25.74%13.84%-6.86%2.53%24.19%0.86%
Jul-7.46%10.40%-5.91%11.92%-2.44%-8.42%-0.32%
Aug-8.10%2.74%-16.92%10.05%37.93%-22.83%0.48%
Sep-0.69%-5.12%-26.44%8.22%2.90%0.18%-3.49%
Oct-24.91%-6.77%-21.50%1.47%8.97%6.13%-6.10%
Nov-44.82%22.11%13.83%33.02%63.03%15.52%*17.11%
Dec-0.68%30.60%3.89%-7.85%16.56%--8.50%
Total-62.89%-44.78%4.45%31.35%72.45%-1.59%-0.17%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $25.39
SMA 50: $23.70
SMA 200: $25.65
Current: $26.06
EMA 12: $26.05
EMA 26: $25.20
MACD: 0.8490 | Signal: -0.0276
BULLISH
ADX (14): 20.99
WEAK TREND
+DI: 21.42
−DI: 17.23

Momentum Oscillators

RSI (14): 57.34
NEUTRAL
Stoch %K: 67.13
Stoch %D: 68.58
Williams %R: -34.39

Volume & Volatility

BB Upper: $28.36
BB Lower: $22.43
NEUTRAL
OBV: 666,327
Vol SMA 20: 243,532
Vol ROC: -54.66%
ATR: $1.04
True Range: $0.99
HV 20: 52.8%
HV 30: 46.8%
HV 60: 37.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before TCMD’s Nov 2 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report: TCMD

Executive Summary BULLISH (Confidence Level: 7)

Key drivers:

  • Strong technical signals, including SMA crossovers and MACD bullish momentum
  • Positive news sentiment from recent headlines
  • Moderate volatility, with a beta of 0.85

Primary risks:

  • Potential for increased competition in the lymphedema solutions market
  • Regulatory changes impacting the medical device industry

Investment thesis: TCMD is a well-positioned company with a strong pipeline of products and services focused on lymphedema management. The recent positive news headlines, combined with moderate volatility, create a favorable risk-reward environment for investors.

Recent news sentiment impact: The positive news headlines have contributed to the bullish momentum in TCMD's stock price, with a cumulative sentiment score of 3.5 out of 5 (POSITIVE).

Technical Analysis Trend Direction:

  • Short-term: Bullish
  • Medium-term: Bullish
  • Long-term: Neutral

Support/Resistance Levels:

  • SMA 20: $24.48 (resistance)
  • SMA 50: $25.84 (resistance)
  • Lower Bollinger Band: $22.32 (support)

Momentum Signals:

  • RSI interpretation: Neutral, indicating no overbought or oversold conditions
  • MACD signal: Bullish momentum, with a reading of -0.30 below the signal line
  • Bollinger Bands position: Squeeze, indicating potential for increased volatility

Volume Analysis:

  • Volume SMA 20: 376202.75 (increasing)
  • On-Balance Volume (OBV): 2703591.28 (increasing)
  • Volume Rate of Change: 102.01% (positive)

News & Sentiment Analysis Recent Headlines Summary:

  • Positive news headlines from Tactile Medical's board expansion, product launches, and acquisitions
  • Neutral headline about institutional support for small caps

Sentiment Assessment: Aggregate sentiment score: 3.5 out of 5 (POSITIVE)

Catalyst Identification: Upcoming earnings release and potential FDA approvals for new products

Market Narrative: The recent positive news headlines have contributed to the bullish momentum in TCMD's stock price, aligning with the company's strong technical signals.

Risk & Volatility Assessment Beta Interpretation: 0.85 (vs SPY), indicating moderate volatility

Volatility Regime: Current volatility is lower than historical levels

Options Market Signals:

  • IV Rank: 18.0% (Low)
  • Current IV: 90.0%
  • Expected Move: $3.08 (38 DTE), 7-DTE: $1.73
  • Volume Flow: 13 calls vs 4 puts
  • Open Interest: 43 calls vs 4 puts
  • Put/Call Volume Ratio: 0.31 (Bullish sentiment)

Downside Protection: Support levels at SMA 20 and Lower Bollinger Band

Market Context & Positioning Sector Performance: TCMD's sector, Medical Devices, has performed relatively well compared to the broader market

Institutional Activity: Increasing volume flow and open interest suggest institutional support for TCMD

Correlation Analysis: TCMD has a moderate correlation with the S&P 500 (R-squared interpretation)

Relative Valuation: TCMD is trading within its historical range, with no clear signs of overvaluation or undervaluation

Key Levels & Action Items Critical Price Levels:

  • SMA 20: $24.48 (resistance)
  • Lower Bollinger Band: $22.32 (support)

Breakout/Breakdown Levels: None identified

Time-Sensitive Catalysts: Upcoming earnings release and potential FDA approvals for new products

Risk Management: Stop-loss levels at SMA 50 and Lower Bollinger Band; position sizing considerations based on risk tolerance.

This comprehensive analysis provides a nuanced view of TCMD's stock, highlighting both the bullish momentum and potential risks. By referencing specific data points, we can gain insights into the company's technical and fundamental performance.

Generated
Earnings History
13 of 20 under expected move
Avg Expected Move
18.09%
Avg Actual Move
14.30%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-23 After-Close 14.79% 5.69% 0.38x Within
2021-08-02 After-Close 9.81% 8.02% 0.82x Within
2021-11-08 After-Close 11.98% 23.01% 1.92x Exceeded
2022-02-22 After-Close 19.01% 16.74% 0.88x Within
2023-02-21 After-Close 6.56% 10.73% 1.64x Exceeded
2023-05-08 After-Close 16.70% 13.34% 0.80x Within
2023-08-07 After-Close 13.45% 12.82% 0.95x Within
2023-11-06 After-Close 11.08% 21.22% 1.92x Exceeded
2024-02-20 After-Close 25.70% 2.25% 0.09x Within
2024-04-23 After-Close 22.17% 3.23% 0.15x Within
2024-08-05 Pre-Market 39.97% 5.87% 0.15x Within
2024-11-04 Pre-Market 23.83% 2.86% 0.12x Within
2025-02-18 After-Close 14.70% 13.27% 0.90x Within
2025-05-05 After-Close 15.96% 28.98% 1.82x Exceeded
2025-08-04 After-Close 14.66% 26.79% 1.83x Exceeded
2025-11-03 After-Close 20.93% 40.65% 1.94x Exceeded
2026-02-17 After-Close 22.37% 17.83% 0.80x Within
2026-05-04 After-Close 19.28% 7.22% 0.37x Within
2026-08-10 After-Close 17.07% 17.12% 1.00x Exceeded
2026-11-02 After-Close 21.75% 8.35% 0.38x Within

Earnings calendar: this week’s reports with expected vs actual moves →

TCMD Options Activity & IV Rank

TCMD IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 54.9%
7-DTE IV: —
Expected Move: $3.20
7-DTE Move: $1.93
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 198
Put Volume: 35
P/C Volume: 0.177
BULLISH
Call OI: 1,852
Put OI: 68
P/C OI: 0.037
Total OI: 1,920

ATM Options Pricing

ATM Call: $2.30
ATM Put: $0.90
Call %: 8.8%
Put %: 3.4%

Chain Summary

Chain Volume: 233
Chain OI: 1,920
Last Updated: 11/19/2026

TCMD Implied Volatility

30-day IV
54.9%
Nov 19
IV rank
28Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much TCMD actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
HIGH γ vs HISTORY

Estimated net dealer gamma is at the 82nd percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
82%
vs own history
GEX tilt
+0.97
OI-weighted, today
Vanna tilt
+0.80
δ-sensitivity to IV
Charm tilt
-0.78
δ-decay vs time
Vanna tilt +0.80: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.78: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 8 ATM contracts, 2k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 59.5% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)27.9MediumNov 19

Embed TCMD IV rank

TCMD's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$3.20Nov 19
Beta Analysis

Risk Metrics

Beta: 1.1044
Alpha: 12.78%
Correlation: 0.3111
R-Squared: 9.7%
Stock Volatility: 48.8%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own TCMD
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$8.0M
0.01%
#1184 of 3151-24.3%13F
Citadel Hedge fund
Ken Griffin
$1.7M
0.00%
#3123 of 6285-13.4%13F
Rockefeller Capital Management Family office
Rockefeller family
$3K
0.00%
#4500 of 48580.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

TCMD Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 23,096,418 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

169 filers44,282,230 shares$1.09B value191.73% of float
# Filer Shares Value % of Total % of Float Period
1 CADIAN CAPITAL MANAGEMENT, LP 3,153,880 $93.92M 8.65% 13.66% 2026-06-30
2 BlackRock, Inc. Custodian 3,846,414 $85.74M 7.90% 16.65% 2026-09-30
3 Morgan Stanley Custodian 3,580,916 $79.82M 7.35% 15.50% 2026-09-30
4 Driehaus Capital Management LLC 1,875,566 $55.85M 5.15% 8.12% 2026-06-30
5 Dimensional Fund Advisors LP Custodian 2,259,130 $50.36M 4.64% 9.78% 2026-09-30
6 Vanguard Capital Management LLC 1,917,016 $42.73M 3.94% 8.30% 2026-09-30
7 ACADIAN ASSET MANAGEMENT LLC 1,503,962 $33.50M 3.09% 6.51% 2026-09-30
8 Vanguard Portfolio Management LLC 1,494,042 $33.30M 3.07% 6.47% 2026-09-30
9 FEDERATED HERMES, INC. 1,419,402 $31.64M 2.91% 6.15% 2026-09-30
10 First Light Asset Management, LLC 925,124 $27.55M 2.54% 4.01% 2026-06-30
11 Arrowstreet Capital, Limited Partnership 1,205,664 $26.87M 2.48% 5.22% 2026-09-30
12 State Street Corp 1,192,336 $26.58M 2.45% 5.16% 2026-09-30
13 Geode Capital Management, LLC Custodian 1,081,498 $24.11M 2.22% 4.68% 2026-09-30
14 Jupiter Topco LLC 794,556 $23.66M 2.18% 3.44% 2026-06-30
15 NEXT CENTURY GROWTH INVESTORS LLC 933,126 $20.80M 1.92% 4.04% 2026-09-30
16 LSV ASSET MANAGEMENT 911,654 $20.32M 1.87% 3.95% 2026-09-30
17 PARADIGM CAPITAL MANAGEMENT INC/NY 901,998 $20.11M 1.85% 3.91% 2026-09-30
18 PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC. 630,000 $18.76M 1.73% 2.73% 2026-06-30
19 Dana Investment Advisors, Inc. 807,548 $18.00M 1.66% 3.50% 2026-09-30
20 RENAISSANCE TECHNOLOGIES LLC 718,000 $16.00M 1.47% 3.11% 2026-09-30
21 Ameriprise Financial, Inc. Custodian 492,530 $14.67M 1.35% 2.13% 2026-06-30
22 PINNACLE ASSOCIATES LTD 655,934 $14.62M 1.35% 2.84% 2026-09-30
23 Goldman Sachs Group Inc Custodian 483,416 $14.40M 1.33% 2.09% 2026-06-30
24 BRIDGEWAY CAPITAL MANAGEMENT, LLC 465,632 $13.87M 1.28% 2.02% 2026-06-30
25 GLOBEFLEX CAPITAL L P 444,596 $13.24M 1.22% 1.93% 2026-06-30
3 filers$1.72M notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $976.78K 56.67% 2026-06-30
2 Susquehanna International Group, LLP Custodian $744.50K 43.20% 2026-06-30
3 Simplex Trading, LLC Custodian $2.23K 0.13% 2026-09-30
2 filers$1.55M notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $1.54M 99.57% 2026-06-30
2 Simplex Trading, LLC Custodian $6.69K 0.43% 2026-09-30

TCMD Insider Trading (Form 4)

Latest: 2026-11-09
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-09 William W Burke Director Sell (S) −5,000 $27.00 -$135.0K EDGAR
2026-11-06 Stephen A. Kiewiet Chief Operating Officer Award (A) +6,438 — EDGAR
2026-11-05 Laura G. King Director Sell (S) −4,800 $25.00 -$120.0K EDGAR
2026-08-12 Sheri Louise Dodd Chief Executive Officer Sell (S) −10,978 $29.44 -$323.2K EDGAR
2026-05-13 Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER Sell (S) −4,631 $24.49 -$113.4K EDGAR
2026-05-08 Laura G. King Director Award (A) +6,521 — EDGAR
2026-05-08 Carmen B Volkart Director Award (A) +6,521 — EDGAR
2026-05-08 Raymond Huggenberger Director Award (A) +6,521 — EDGAR
2026-05-08 Valerie L. Asbury Director Award (A) +6,521 — EDGAR
2026-05-08 William W Burke Director Award (A) +6,521 — EDGAR
2026-05-08 Andrea Pearson Director Award (A) +6,521 — EDGAR
2026-05-08 David Brent Shafer Director Award (A) +6,521 — EDGAR
2026-05-08 Boyd Vindell Washington Director Award (A) +6,521 — EDGAR
2026-03-11 Andrea Pearson Director Award (A) +852 — EDGAR
2026-02-26 Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER Sell (S) −7,701 $28.94 -$222.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

TCMD Insider Holdings

13 insiders · @ $26.06
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Sheri Louise Dodd Chief Executive Officer 232,907 $6.07M -$1.20M 13 2026-08-12
2 Daniel L. Reuvers President and CEO 214,604 $5.59M -$1.18M 15 2025-03-13
3 Elaine M. Birkemeyer CHIEF FINANCIAL OFFICER 130,188 $3.39M -$648.6K 11 2026-05-13
4 Kristie Burns Sr. VP Mktg & Clinical Affairs 82,581 $2.15M -$779.2K 16 2026-02-26
5 Raymond Huggenberger Director 62,841 $1.64M $0 10 2026-05-08
6 David Brent Shafer Director 55,343 $1.44M $0 6 2026-05-08
7 Valerie L. Asbury Director 55,343 $1.44M $0 6 2026-05-08
8 William W Burke Director 50,041 $1.30M -$1.82M 25 2026-11-09
9 Carmen B Volkart Director 44,219 $1.15M $0 5 2026-05-08
10 Boyd Vindell Washington Director 41,768 $1.09M $0 4 2026-05-08
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

TCMD Board & Officers

As of SEC filings through Nov 9, 2026

Directors 9

Officers 4

Changes in the last 10 years (41)
Nov 2, 2026Stephen A. Kiewiet became Chief Operating Officer
Mar 9, 2026Andrea Pearson became a director
Jan 13, 2025Laura G. King became a director
Aug 9, 2024Sheri Louise Dodd first listed as Chief Executive Officer in an SEC filing
Apr 23, 2024The company announced the departure of Daniel L. Reuvers as President and CEO in an SEC filing
Oct 2, 2023Boyd Vindell Washington became a director
Jul 31, 2023Sherri Lee Ferstler became Senior VP, Sales
Jul 14, 2023The company announced the departure of Eric Pauls as Senior VP, Sales in an SEC filing
Mar 20, 2023Elaine M. Birkemeyer became Chief Financial Officer
Mar 14, 2023The company announced the departure of Brent Moen as Chief Financial Officer in an SEC filing
Jan 5, 2023Carmen B Volkart became a director
Jan 5, 2022Valerie L. Asbury became a director
Jan 5, 2022The company announced the departure of Richard Nigon from the board in an SEC filing
Jan 5, 2022The company announced the departure of Peter H Soderberg from the board in an SEC filing
Jan 5, 2022The company announced the departure of Kevin H Roche from the board in an SEC filing
Jan 5, 2022David Brent Shafer became a director
May 1, 2021Kristie Burns became Sr. VP Mktg & Clinical Affairs
May 1, 2021Eric Pauls became Senior VP, Sales
Jan 1, 2021Sheri Louise Dodd became a director
Jan 1, 2021Deepti Jain became a director
Not reported recently (10)
  • Daniel L. Reuvers · Last reported as a director in an SEC filing dated Mar 13, 2025
  • Sherri Lee Ferstler · Last reported as Senior VP, Sales in an SEC filing dated Aug 14, 2024
  • Deepti Jain · Last reported as a director in an SEC filing dated May 11, 2022
  • Bryan Rishe · Last reported as SVP, Sales in an SEC filing dated Mar 9, 2021
  • Cheryl Pegus · Last reported as a director in an SEC filing dated May 6, 2020
  • Gerald R. Mattys · Last reported as a director in an SEC filing dated Apr 30, 2020
  • Robert J. Folkes · Last reported as Chief Operating Officer in an SEC filing dated Mar 13, 2020
  • Maggie Thompson · Last reported as SVP, Reimb. & Payer Relations in an SEC filing dated May 14, 2019
  • Lynn Larson Blake · Last reported as Chief Financial Officer in an SEC filing dated Aug 20, 2018
  • Stephen I Shapiro · Last reported as a director in an SEC filing dated Mar 6, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

TCMD Proposed Insider Sales (Form 144)

Latest: 2026-11-03
Last 30d: 1 filing · $120K notice value  ·  Last 90d: 2 filings · $120K notice value · 2 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: King Laura G. (1, $120K) · William W Burke (1)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-11-03 King Laura G. Director 4,800 $120.0K 2026-11-03 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-08-20 William W Burke board of director 15,000 — 2026-08-19 Merrill Lynch 10b5-1 EDGAR
2026-08-10 Dodd Sheri Louise Officer, Director 10,978 $323.2K 2026-08-10 Fidelity Brokerage Services LLC — EDGAR
2026-05-11 Birkemeyer Elaine M. Officer 4,631 $113.4K 2026-05-11 Fidelity Brokerage Services LLC — EDGAR
2026-02-25 Burns Kristie Officer 4,000 $113.9K 2026-02-25 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-02-24 Dodd Sheri Louise Officer, Director 10,993 $318.1K 2026-02-24 Fidelity Brokerage Services LLC — EDGAR
2026-02-24 Birkemeyer Elaine M. Officer 7,701 $222.9K 2026-02-24 Fidelity Brokerage Services LLC — EDGAR
2026-02-24 Burns Kristie Officer 6,246 $180.8K 2026-02-24 Fidelity Brokerage Services LLC — EDGAR
2026-02-23 Burns Kristie Officer 4,439 $125.6K 2026-02-23 Fidelity Brokerage Services LLC — EDGAR
2026-02-23 Dodd Sheri Louise Officer, Director 15,240 $431.2K 2026-02-23 Fidelity Brokerage Services LLC — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-02
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-02 Earnings results EDGAR
2026-08-10 Earnings results EDGAR
2026-07-13 Regulation FD disclosure · Other events EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-02 0001104659-26-121325 EDGAR
2026-08-10 0001104659-26-093352 EDGAR
ETF Holders
66 ETFs hold TCMD
25 shown · $91.90M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.02% $15.8M $74.3B 2026-11-16
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $12.4M — 2026-10-31
3 DFAT Dimensional US Targeted Value ETF Dimensional 0.03% $8.5M — 2026-11-16
4 DFSV Dimensional US Small Cap Value ETF Dimensional 0.02% $6.6M — 2026-11-16
5 VXF Vanguard Extended Market ETF Vanguard 0.01% $5.8M — 2026-10-31
6 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.04% $4.8M $13.4B 2026-11-16
7 DFAS Dimensional US Small Cap ETF Dimensional 0.01% $4.4M — 2026-11-16
8 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.06% $4.0M $6.7B 2026-11-16
9 BSVO EA Bridgeway Omni Small-Cap Value ETF Nport 0.15% $3.6M — 2026-06-30
10 VTWO Vanguard Russell 2000 ETF Vanguard 0.02% $3.1M — 2026-10-31
11 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $2.4M — 2026-11-16
12 DFMC Dimensional US Micro Cap ETF Dimensional 0.02% $1.8M — 2026-11-16
13 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.16% $1.8M $1.2B 2026-11-16
14 NANC Unusual Whales Subversive Democratic Trading ETF Nport 0.64% $1.8M — 2026-06-30
15 VFMF Vanguard U.S. Multifactor ETF Vanguard 0.15% $1.8M — 2026-11-16
16 FSCC Federated Hermes MDT Small Cap Core ETF Nport 0.43% $1.6M — 2026-08-31
17 VHT Vanguard Health Care ETF Vanguard 0.01% $1.6M — 2026-10-31
18 XHE State Street® SPDR® S&P® Health Care Equipment ETF SPDR (State Street) 1.01% $1.6M $154.2M 2026-11-16
19 AVUV Avantis U.S. Small Cap Value ETF Avantis 0.00% $1.5M $32.1B 2026-11-16
20 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.04% $1.4M $3.2B 2026-11-16
21 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.07% $1.3M — 2026-11-16
22 PSC Principal U.S. Small-Cap ETF Nport 0.05% $1.2M — 2026-06-30
23 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.10% $1.0M $1.0B 2026-11-16
24 VAMO Cambria Value and Momentum ETF Nport 0.93% $1.0M — 2026-07-31
25 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $968,781 $13.5B 2026-11-16
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
25.58
TTM Diluted EPS
$1.02
TTM Revenue
$356.42M
TTM Net Income
$23.82M
TTM Op. Cash Flow
$32.19M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$91.86M$7.16M$0.31$11.98M
Q2 '262026-06-30$85.70M$7.79M$0.34$3.25M
Q1 '262026-03-31$75.27M$-1.76M$-0.08$-339.00K
Q4 '252025-12-31$103.59M$10.63M$0.45$17.30M
Q3 '252025-09-30$85.75M$8.21M$0.36$10.34M
Q2 '252025-06-30$78.91M$3.22M$0.14$14.76M
Q1 '252025-03-31$61.27M$-2.97M$-0.13$417.00K
Q4 '242024-12-31$85.58M$9.72M$0.40$16.33M
Q3 '242024-09-30$73.09M$5.16M$0.21$10.26M
Q2 '242024-06-30$73.22M$4.30M$0.18$13.14M
Q1 '242024-03-31$61.09M$-2.21M$-0.09$924.00K
Q4 '232023-12-31$77.65M$8.20M$0.35$18.35M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-02
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
25.58
P/B
2.65
P/S
1.69
EV/EBITDA
12.46
EV/Sales
1.48
ROE
10.5%
ROA
8.2%
Div Yield
0.00%
FCF Yield
5.34%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$602.59M
as of 2026-11-19

TCMD vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
ISRG Intuitive Surgical Inc. $145.9B 49.1 +20.5% −27.8% 28
IDXX Idexx Laboratories Inc $55.0B 46.4 +11.9% +2.8% 27
GEHC GE HealthCare Technologies Inc. Common S $37.8B 17.3 +6.9% −1.1% 19
GKOS Glaukos Corporation $13.8B — +46.9% +114.2% 26
OSCR Oscar Health, Inc. $8.6B 12.3 +54.9% +73.6% 16
HAE Haemonetics Corporation $5.6B 53.9 +4.1% +51.0% 16
MD Pediatrix Medical Group, Inc. $2.4B 16.2 +1.9% +40.3% 31
ENOV Enovis Corporation $1.6B — +3.3% −1.1% 40
TCMD Tactile Systems Technology, Inc. $592M 25.5 +14.4% −4.9% 28
Peer median $11.2B 31.9 +9.4% +21.6% 27

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
2.79M
SI % of Float
12.61%
Days to Cover
16.72
Short Vol Ratio
44.8%
Free Float
22.11M
Float %
97.6%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-08-14